Archives
-
XPG Mutations, Ribosome Stress, and Cockayne Syndrome
2026-09-30
This study distinguishes a Cockayne syndrome phenotype from an XP-only phenotype caused by mutations in the same XPG gene. Its central contribution is linking the Cockayne syndrome cellular state to defective RNA polymerase I activity, impaired rRNA maturation, eIF2α phosphorylation, and a shift toward IRES-dependent translation, thereby implicating ribosomal stress and translational control in disease pathogenesis.
-
HRP Goat Anti-Rabbit IgG (H+L) Antibody
2026-09-30
HRP Goat Anti-Rabbit IgG (H+L) Antibody provides an HRP-labeled secondary reagent for detecting rabbit IgG primary antibodies in Western blot, ELISA, IHC, and ICC workflows. It should be used with rabbit primaries and assay-appropriate controls, not as a universal secondary antibody, diagnostic reagent, or substitute for primary-antibody validation.
-
ELISA Stop Solution in Quantitative Immunoassays
2026-09-29
Learn how ELISA Stop Solution controls endpoint chemistry, improves plate-to-plate consistency, and supports interpretation of vaccine immunogenicity data. This guide connects assay design with findings from a bivalent H5/H7 mRNA–LNP vaccine study.
-
3X (DYKDDDDK) Peptide: Workflow Guide
2026-09-29
Use the 3X FLAG peptide to improve competitive elution, confirm FLAG fusion proteins, and control metal-sensitive immunoassays. This practical guide connects recombinant protein workflows with structural insights from human PSS2 research, while emphasizing assay controls and troubleshooting.
-
ASB3 Targets MAVS to Suppress Antiviral Immunity
2026-09-28
The 2024 Cell Death & Differentiation study identifies ASB3 as an E3 ubiquitin ligase that suppresses antiviral innate immunity by promoting K48-linked ubiquitination and proteasomal degradation of MAVS at K297. Its genetic, biochemical, infection, and animal-model evidence positions ASB3 as a negative regulator of RIG-I-like receptor signaling and provides a framework for experimentally validating MAVS-centered antiviral mechanisms.
-
NETosis and IL-36R Feedback in Psoriasis
2026-09-28
The study links TLR3- and P2X7R-associated signals to neutrophil extracellular trap formation and identifies IL-36R signaling as an amplifier of inflammatory responses in psoriasis models. Its findings support further investigation of the NET–IL-36R relationship while highlighting the importance of disease timing and model-specific validation.
-
Homoharringtonine Against SARS-CoV-2: Evidence and Limits
2026-09-27
A 2025 study reports that homoharringtonine suppressed replication of four tested coronaviruses and was associated with rapid upper-respiratory SARS-CoV-2 clearance in mouse and small human cohorts. The findings support further investigation of this protein-elongation inhibitor as a locally delivered antiviral candidate, but do not establish clinical efficacy, safety, or first-line use.
-
FITC Goat Anti-Rabbit IgG (H+L) Antibody Workflows
2026-09-26
Translate a mechanistic study of lycopene and T-2 toxin into practical fluorescence assays for testicular and Leydig-cell research. This guide shows how to use a FITC secondary for rabbit-primary detection, with starting conditions, controls, and troubleshooting that keep biological interpretation separate from reagent performance.
-
Western Secondary Antibody Dilution Buffer for Blots
2026-09-25
Improve Western blot consistency when testing macrophage inflammatory pathways with a secondary antibody diluent formulated to limit background and support antibody reuse. This workflow connects the octanal–Olfr2–NHE1 atherosclerosis findings to practical protein-detection choices without confusing assay optimization with biological evidence.
-
Dietary Arachidonic Acid Boosts Vaccine Humoral Immunity
2026-09-25
The study reports that dietary arachidonic acid (ARA) enhances rabies-vaccine neutralizing antibody responses in mice and accelerates antibody development in human volunteers. Its mechanistic findings implicate lymph-node ARA metabolism and a prostaglandin I2–cAMP–PKA pathway affecting B-cell activation, while leaving dose, safety, and generalizability questions for further study.
-
Batimastat (BB-94) and Local BDNF Processing
2026-09-24
Explore how Batimastat (BB-94) can help test the role of extracellular MMP activity in spatially organized BDNF processing at developing neuromuscular junctions. This article separates evidence from hypothesis and translates a recent study into practical assay-design decisions.
-
3X FLAG Peptide for Membrane-Protein Research
2026-09-24
The 3X (DYKDDDDK) Peptide can support detection and recovery of tagged proteins, but membrane-contact biology demands careful assay design. Using MIGA2 lipid-transfer research as a case study, this article explains how to separate tag performance from protein function and lipid-dependent assay effects.
-
Homoharringtonine Against SARS-CoV-2: Evidence and Limits
2026-09-23
A 2025 study reports that homoharringtonine inhibited replication of four tested coronaviruses and reduced SARS-CoV-2 in animal and small human cohorts after upper-respiratory delivery. The findings support further investigation of a locally administered antiviral strategy, but the clinical observations are preliminary and do not establish efficacy or safety for routine COVID-19 treatment.
-
Microplastics, Nanoplastics, and Pulmonary Fibrosis
2026-09-23
This study compares polystyrene, polyethylene, and polypropylene microplastics and nanoplastics in mouse and BEAS-2B lung models, showing that polymer identity and particle size shape pulmonary toxicity. Its strongest mechanistic contribution is the identification of FXR-YAP1 dysregulation as a potential pathway linking polystyrene nanoplastic exposure with inflammatory and fibrotic responses.
-
NETs and IL-36R Feedback in Psoriasis
2026-09-22
The reference study identifies a mechanistic feedback loop in which TLR3- and P2X7R-linked signals promote NET formation, while IL-36R activity amplifies cutaneous inflammation. Its combined neutrophil, keratinocyte, and mouse-model experiments support NET–IL-36R signaling as a potential therapeutic axis, while also highlighting the importance of disease timing and model limitations.